Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
ACXP Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.80 - $44.00
Previous CloseN/A
Volume243.54K
Average Volume (3M)78.57K
Market Cap
$6.12M
Enterprise Value$6.10M
Total Cash (Recent Filing)$6.06M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.39
Next Earnings
Nov 18, 2025EPS Estimate
-1.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.89
Shares Outstanding1,584,775
10 Day Avg. Volume103,831
30 Day Avg. Volume78,573
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$30.50Price Target Upside690.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentIbezapolstat demonstrated a 94% clinical cure rate and no recurrence at 30 days, a key measure in CDI antibiotic development.
Funding And PartnershipsAcurx should be able to find a partner for its development program, enhancing its prospects for growth and collaboration.
Regulatory ApprovalRegulatory agencies in the U.S. and the E.U. have provided positive feedback to Acurx, supporting topics and plans related to manufacturing, non-clinical, and clinical aspects of the Phase 3 program and trial design.
Bears Say
Funding RequirementsThere needs to be a substantial capital raise and/or other funding resources to initiate a P3 program.
Market ValuationA combination of macro- and micro- factors have contributed to significant pullbacks in valuations, including ACXP shares which are at an all-time low.
Acurx Pharmaceuticals News
ACXP FAQ
What was Acurx Pharmaceuticals’s price range in the past 12 months?
Acurx Pharmaceuticals lowest stock price was $3.80 and its highest was $44.00 in the past 12 months.
What is Acurx Pharmaceuticals’s market cap?
Acurx Pharmaceuticals’s market cap is $6.12M.
When is Acurx Pharmaceuticals’s upcoming earnings report date?
Acurx Pharmaceuticals’s upcoming earnings report date is Nov 18, 2025 which is in 73 days.
How were Acurx Pharmaceuticals’s earnings last quarter?
Acurx Pharmaceuticals released its earnings results on Aug 12, 2025. The company reported -$1.89 earnings per share for the quarter, beating the consensus estimate of -$2.333 by $0.443.
Is Acurx Pharmaceuticals overvalued?
According to Wall Street analysts Acurx Pharmaceuticals’s price is currently Undervalued.
Does Acurx Pharmaceuticals pay dividends?
Acurx Pharmaceuticals does not currently pay dividends.
What is Acurx Pharmaceuticals’s EPS estimate?
Acurx Pharmaceuticals’s EPS estimate is -1.31.
How many shares outstanding does Acurx Pharmaceuticals have?
Acurx Pharmaceuticals has 1,584,775 shares outstanding.
What happened to Acurx Pharmaceuticals’s price movement after its last earnings report?
Acurx Pharmaceuticals reported an EPS of -$1.89 in its last earnings report, beating expectations of -$2.333. Following the earnings report the stock price went down -0.893%.
Which hedge fund is a major shareholder of Acurx Pharmaceuticals?
Currently, no hedge funds are holding shares in ACXP
Company Description
Acurx Pharmaceuticals
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
ACXP Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted several positive developments, including a new patent, additional funding, and significant clinical trial results. Financial results showed improvement with increased cash reserves and reduced expenses. However, challenges such as the reverse stock split and strategic delays in clinical trials were noted. Overall, the sentiment is cautiously optimistic.View all ACXP earnings summariesACXP Stock 12 Month Forecast
Average Price Target
$30.50
▲(690.16% Upside)
Technical Analysis
Ibio
―
Windtree Therapeutics
―
BioRestorative Therapies
―
Lixte Biotechnology Holdings
―
Bolt Biotherapeutics
―
Ownership Overview
8.10% Insiders
2.23% Mutual Funds
0.37% Other Institutional Investors
87.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---